Cart
sales@molnova.com
Sulfatinib (b)
CAS No. 1308672-74-3
Sulfatinib (b)( HMPL-012 | Surufatinib | HMPL012 )
Catalog No. M11232 CAS No. 1308672-74-3
Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 72 | In Stock |
|
| 5MG | 68 | In Stock |
|
| 10MG | 92 | In Stock |
|
| 25MG | 151 | In Stock |
|
| 50MG | 222 | In Stock |
|
| 100MG | 346 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSulfatinib (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionSulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively.
-
DescriptionSulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively; also potently inhibits TrkB and FLT-3 with IC50 of 41 and 67 nM, shows little to no activity against other 278 other kinases (IC50>150 nM); targets tumor angiogenesis and immune modulation, exhibits an acceptable safety profile and encouraging antitumor activity in clinical investigations.Brain Cancer Phase 3 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsHMPL-012 | Surufatinib | HMPL012
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research AreaCancer
-
IndicationBrain Cancer
Chemical Information
-
CAS Number1308672-74-3
-
Formula Weight480.5825
-
Molecular FormulaC24H28N6O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 30 mg/mL
-
SMILESCC1=CC2=C(N1)C=CC(OC3=NC(NC4=CC(CS(NCCN(C)C)(=O)=O)=CC=C4)=NC=C3)=C2
-
Chemical NameBenzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1H-indol-5-yl)oxy]-2-pyrimidinyl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xu JM, et al. Oncotarget. 2017 Jun 27;8(26):42076-42086.
molnova catalog
related products
-
Cabozantinib (S-mala...
Cabozantinib (XL184) is a potent, multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
-
Regorafenib hydrochl...
Regorafenib hydrochloride (BAY73-4506) is a potent, orally active multikinase inhibitor.
-
PKI-166
PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.
